(KROS) Keros Therapeutics - Overview
Stock: KER-050, KER-012, KER-065, Elritercept
| Risk 5d forecast | |
|---|---|
| Volatility | 59.7% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.10 |
| Alpha | -20.74 |
| Character TTM | |
|---|---|
| Beta | 0.883 |
| Beta Downside | 1.281 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.45% |
| CAGR/Max DD | -0.42 |
EPS (Earnings per Share)
Revenue
Description: KROS Keros Therapeutics March 03, 2026
Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharma focused on novel therapies that modulate the transforming growth factor-beta (TGF-β) signaling pathway. Its lead candidate, KER-050, targets cytopenias-including anemia and thrombocytopenia-in myelodysplastic syndromes (MDS) and myelofibrosis. The pipeline also includes KER-012 (Phase II for pulmonary arterial hypertension and related cardiovascular disorders) and KER-065 (Phase I for neuromuscular diseases), plus a collaborative agreement with Hansoh Healthtech to develop and commercialize elritercept-based products.
As of the most recent quarter (Q4 2025), Keros reported $115 million in cash and cash equivalents, providing runway into mid-2027 under current burn rates. The Phase II data for KER-050 released in early 2025 showed a 45% improvement in transfusion-independent status among MDS patients, exceeding the primary endpoint. The company’s market capitalization stands around $350 million, and its stock has traded at a forward-price-to-sales multiple of roughly 12×, reflecting investor optimism about TGF-β-targeted therapeutics.
The biotechnology sector continues to benefit from strong R&D tax credits and a surge in venture capital directed at rare-disease and hematology programs, which supports Keros’s growth prospects. For deeper quantitative analysis, you may want to explore the ValueRay platform.
Headlines to watch out for
- KER-050 clinical trial results directly impact stock valuation
- Regulatory approval for KER-050 drives revenue potential
- KER-012 and KER-065 pipeline progress influences future growth
- Collaboration with Hansoh Healthtech expands market access
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 87.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 57.78 > 1.0 |
| NWC/Revenue: 120.9% < 20% (prev 15.8k%; Δ -15.7k% < -1%) |
| CFO/TA 0.32 > 3% & CFO 107.5m > Net Income 87.0m |
| Net Debt (-270.5m) to EBITDA (82.7m): -3.27 < 3 |
| Current Ratio: 15.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.9m) vs 12m ago -6.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 51.17% > 50% (prev 0.58%; Δ 50.59% > 0%) |
| Interest Coverage Ratio: -7.62 > 6 (EBITDA TTM 82.7m / Interest Expense TTM -10.7m) |
Altman Z'' -12.28
| A: 0.87 (Total Current Assets 315.4m - Total Current Liabilities 20.4m) / Total Assets 338.0m |
| B: -1.43 (Retained Earnings -481.8m / Total Assets 338.0m) |
| C: 0.17 (EBIT TTM 81.2m / Avg Total Assets 477.0m) |
| D: -13.81 (Book Value of Equity -481.8m / Total Liabilities 34.9m) |
| Altman-Z'' Score: -12.28 = D |
Beneish M 1.00
| DSRI: 0.02 (Receivables 6.37m/4.46m, Revenue 244.1m/3.55m) |
| GMI: 0.66 (GM 99.38% / 65.38%) |
| AQI: 0.75 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 68.75 (Revenue 244.1m / 3.55m) |
| TATA: -0.06 (NI 87.0m - CFO 107.5m) / TA 338.0m) |
| Beneish M-Score: 44.23 (Cap -4..+1) = D |
What is the price of KROS shares?
Over the past week, the price has changed by -2.84%, over one month by -32.28%, over three months by -45.60% and over the past year by -3.52%.
Is KROS a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KROS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.6 | 99% |
| Analysts Target Price | 22.6 | 99% |
KROS Fundamental Data Overview March 18, 2026
P/E Forward = 48.7805
P/S = 1.3769
P/B = 0.7175
Revenue TTM = 244.1m USD
EBIT TTM = 81.2m USD
EBITDA TTM = 82.7m USD
Long Term Debt = 16.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.41m USD (from shortTermDebt, last quarter)
Debt = 16.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -270.5m USD (from netDebt column, last quarter)
Enterprise Value = 65.5m USD (336.0m + Debt 16.9m - CCE 287.4m)
Interest Coverage Ratio = -7.62 (Ebit TTM 81.2m / Interest Expense TTM -10.7m)
EV/FCF = 0.62x (Enterprise Value 65.5m / FCF TTM 106.0m)
FCF Yield = 161.7% (FCF TTM 106.0m / Enterprise Value 65.5m)
FCF Margin = 43.41% (FCF TTM 106.0m / Revenue TTM 244.1m)
Net Margin = 35.65% (Net Income TTM 87.0m / Revenue TTM 244.1m)
Gross Margin = unknown ((Revenue TTM 244.1m - Cost of Revenue TTM 1.51m) / Revenue TTM)
Tobins Q-Ratio = 0.19 (Enterprise Value 65.5m / Total Assets 338.0m)
Interest Expense / Debt = -63.18% (Interest Expense -10.7m / Debt 16.9m)
Taxrate = 5.31% (4.88m / 91.9m)
NOPAT = 76.9m (EBIT 81.2m * (1 - 5.31%))
Current Ratio = 15.45 (Total Current Assets 315.4m / Total Current Liabilities 20.4m)
Debt / Equity = 0.06 (Debt 16.9m / totalStockholderEquity, last quarter 303.1m)
Debt / EBITDA = -3.27 (Net Debt -270.5m / EBITDA 82.7m)
Debt / FCF = -2.55 (Net Debt -270.5m / FCF TTM 106.0m)
Total Stockholder Equity = 610.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.24% (Net Income 87.0m / Total Assets 338.0m)
RoE = 14.25% (Net Income TTM 87.0m / Total Stockholder Equity 610.6m)
RoCE = 12.95% (EBIT 81.2m / Capital Employed (Equity 610.6m + L.T.Debt 16.9m))
RoIC = 12.60% (NOPAT 76.9m / Invested Capital 610.6m)
WACC = 8.73% (E(336.0m)/V(352.9m) * Re(9.17%) + (debt cost/tax rate unavailable))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.10%
[DCF] Terminal Value 78.92% ; FCFF base≈106.0m ; Y1≈130.7m ; Y5≈222.6m
[DCF] Fair Price = 179.8 (EV 3.27b - Net Debt -270.5m = Equity 3.55b / Shares 19.7m; r=8.73% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 36.67 | EPS CAGR: 7.02% | SUE: -0.12 | # QB: 0
Revenue Correlation: 60.99 | Revenue CAGR: 172.8% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.16 | Chg7d=-0.298 | Chg30d=-0.298 | Revisions Net=-4 | Analysts=5
EPS current Year (2026-12-31): EPS=-4.67 | Chg7d=-0.785 | Chg30d=-1.235 | Revisions Net=+1 | Growth EPS=-303.2% | Growth Revenue=-98.7%
EPS next Year (2027-12-31): EPS=-5.05 | Chg7d=-0.825 | Chg30d=-0.825 | Revisions Net=-3 | Growth EPS=-8.1% | Growth Revenue=+266.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -11.7% (Discount Rate 9.2% - Earnings Yield 20.9%)
[Growth] Growth Spread = -85.6% (Analyst -97.2% - Implied -11.7%)